Opiate Dependence Clinical Trial
Official title:
Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia
A randomized clinical trial evaluating whether Behavioral Drug and HIV Risk Reduction Counseling (BDRC), abstinence-contingent take-home buprenorphine (ACB), or the combination of the two improve efficacy and cost-effectiveness of standard buprenorphine treatment for opiate-dependent individuals in Malaysia.
Heroin and injection drug use (IDU) are highly prevalent and driving the HIV epidemic in Malaysia and other countries in the region. In our original RCT, buprenorphine was superior to naltrexone and placebo in treatment retention, weeks of consecutive abstinence and time to heroin use. However, there is room for improvement, since only 50% of subjects assigned to buprenorphine and counseling remained in treatment for 6 months; only 28% avoided relapse to heroin; and treatment reduced drug- but not sex-related HIV risk behaviors. In actual clinical practice in Malaysia and the U.S. buprenorphine treatment effectiveness may be even less, because buprenorphine is provided with relatively minimal psychosocial services (often brief physician management (PM) alone, without additional counseling), and without additional behavioral interventions or contingency management. Hence, we propose a follow up study to evaluate whether standard buprenorphine treatment (consisting of buprenorphine provision, PM, and non-contingent provision of take-home doses of buprenorphine, NCB) is sufficient or whether one or a combination of two behavioral treatments--behavioral drug and HIV risk reduction counseling (BDRC) or abstinence-contingent take-home buprenorphine (ACB)-improve its efficacy. BDRC utilizes short-term behavioral contracts to promote abstinence and reduce drug- and sex-related HIV risk behaviors and can be provided by nurses and medical assistants available in medical settings in Malaysia. ACB, a low cost and feasible alternative to non-contingent take-home buprenorphine (NCB), retains many of its advantages--abstinent patients manage their medication supplies outside of the clinic--but ACB also provides positive incentives for abstinence and directly observed buprenorphine for those with continuing heroin use. In the proposed 2X2 study, heroin dependent patients (N=240) will be inducted onto buprenorphine (weeks 1-2) and then randomized to PM with NCB, PM with ACB, PM with BDRC and NCB, or PM with BDRC and ACB (weeks 3-26). Primary outcome measures include reductions in heroin use (percent days abstinent, proportion of opiate-negative urine tests) and reductions in drug- and sex-related HIV risk behaviors. Data analyses will focus on the intention-to treat sample. The study results will inform practice guidelines and policies regarding buprenorphine treatment. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Completed |
NCT01690546 -
Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence
|
Phase 2 | |
Completed |
NCT01442493 -
Reengineering Methadone Treatment Study of Patient-centered Methadone Treatment
|
N/A | |
Completed |
NCT01389167 -
Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia
|
Phase 3 | |
Completed |
NCT01182402 -
Electronic Compliance Monitoring in Opioid Substitution Treatment
|
N/A | |
Completed |
NCT00987961 -
Linking Hospitalized Injection Drug Users to Buprenorphine
|
Phase 3 | |
Completed |
NCT00634803 -
Clinical Trial of Integrated Treatment for Pain and Opioid Dependence
|
Phase 1/Phase 2 | |
Completed |
NCT00577408 -
Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone
|
Phase 3 | |
Completed |
NCT00566969 -
Cocaine Withdrawal and Pharmacotherapy Response
|
N/A | |
Completed |
NCT00757744 -
Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China
|
Phase 3 | |
Recruiting |
NCT00241930 -
Integrating Buprenorphine Into HIV Treatment
|
Phase 4 | |
Completed |
NCT00218621 -
The Effects of Methadone and Buprenorphine on Fetal Neurobehavior and Infant Neonatal Abstinence Syndrome - 1
|
Phase 2 | |
Completed |
NCT00406484 -
Brief Introductory Therapy for Opioid Dependence
|
Phase 2 | |
Completed |
NCT00580827 -
Clinical Efficacy of Disulfiram in LAAM-Maintained Cocaine Abusers
|
N/A | |
Completed |
NCT03015597 -
Pilot Study of Contingency Management for Smoking Cessation
|
N/A | |
Completed |
NCT01393392 -
Developing a Smoking Cessation Intervention for Methadone Maintained Smokers
|
Phase 1 | |
Completed |
NCT01416584 -
A Bridge to Treatment: The Therapeutic Workplace and Methadone Treatment
|
N/A | |
Recruiting |
NCT00439049 -
Substance Abuse Pre-Treatment Screening Study
|
||
Withdrawn |
NCT00398008 -
HIV Risk Reduction and Drug Abuse Treatment in Iran
|
Phase 2 | |
Completed |
NCT00622596 -
Prospective Cohort of Opiate Dependent Patients on Buprenorphine/Naloxone for Maintenance
|
N/A |